Cannabis Alert: Hexo (TSX:HEXO) Is Poised to Soar More Than 70%

Hexo stock appears to have the upper hand against its rivals. Besides the stock’s outperformance in 2021, the company has a well-laid plan to become the top-three global cannabis products company.

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The majority of cannabis players, including industry leaders, are major disappointments thus far in 2021. After the blazing rally in February 2021, most weed stocks plunged to new lows. Nonetheless, competition remains intense in the pursuit of market dominance.

The much-awaited game changer is the federal legalization of marijuana in the United States. If it happens, Canadian producers will compete with their American counterparts for market share. According to ResearchAndMarkets.com, the worldwide cannabis industry is projected to be worth US$90.4 billion by 2026.

If you size up the top players today, Hexo (TSX:HEXO)(NYSE:HEXO) appears to have the upper hand. The weed stock outperforms (+71.73%) Aurora Cannabis (+12.64%) and Canopy Growth (+0.38%). Aphria and Tilray recently merged, so the integration is ongoing.

Grand plans

Hexo currently trades at $8.02 per share. If you own the stock, market analysts recommend a hold rating. They forecast the price to climb 74.6% to $14 in the next 12 months. On May 28, 2021, the company announced the acquisition of Redecan, the country’s largest privately owned licensed producer.

The deal is worth $925 million, payable in cash and through the issuance of Hexo common shares. Sebastien St-Louis, Hexo’s CEO and co-founder, believes the acquisition will bolster the company’s desire to be the number one licensed producer by recreational market share.

St-Louis is confident the business combination will reinforce Hexo’s position as an industry leader. Redecan is one of the most robust brand portfolios in the country. It should also create a robust foundation for growth, efficiency at scale, and improved financial results.

Moreover, it would mean that Hexo would hold the number one market share in Canadian recreational cannabis and lead in four of Canada’s largest markets. Hexo expects Redecan’s lean production capabilities to drive improved future financial performance and enhance potential to generate cash flow.

Primary goal

St-Louis further adds that Hexo will be at the forefront of the evolving adult-use industry in Canada. By leveraging the combined expertise of Hexo and Redecan, the company could keep up with the rapid pace. The benefit to consumers would be a diverse and innovative range of high-quality products.

Management’s primary goal is to become a top-three global cannabis products company while driving shareholder value. The keys to achieving the goal are to expand its cutting-edge consumer packaged goods (CPG) partnerships and grow the international footprint.

Hexo is also looking to implement a private label strategy, which should be an integral part of its expansion plan in the United States. The company is aware that rivals Canopy Growth, Aurora Cannabis, and Tilray are likewise have all eyeing the same lucrative markets.

The counter move is the purchase of a 50,000-square-foot cannabis production facility in northern Colorado. The company will grant U.S. CPG brands access to Hexo’s technology.

Positive EBITDA

In the first six months of fiscal 2021 (month ended January 31, 2021), Hexo reported a net loss of $25.03 million versus the $358.3 million net loss in the same period last year. Notably, the positive EBITDA in Q2 fiscal 2020 was the seventh consecutive quarter that Hexo registered an improved adjusted EBITDA.

The company will report its Q3 fiscal 2022 earnings on June 14, 2021. It should be worth watching, because another positive result could send the price soaring.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool recommends HEXO Corp.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »